Clinical Trial

Randomization to Extend Stroke Intravenous ThromboLysis In Evolving Non-Large Vessel Occlusion With TNK (RESILIENT

Study acronym: EXTEND-IV
Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated April 4, 2025 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
A phase III, randomized, multi-center clinical trial that will examine whether treatment with intravenous TNK is superior to placebo in patients who suffer a non-large vessel occlusion ischemic stroke within 4.5-12 hours from time last seen well. The randomization employs a 1:1 ratio of intravenous thrombolysis with Tenecteplase (TNK) versus placebo in patients who suffer a non-large vessel occlusion ischemic stroke between 4.5 and 12 hours from time last seen well (TLSW) and with a clinical-radiological mismatch or evidence of salvageable brain tissue on perfusion imaging.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-01-05; most recent amendment 2025-04-02.
Status change: Not Yet Recruiting → Recruiting 2022-04-18
Trial Details
NCT Number NCT05199662
Lead Sponsor Hospital Moinhos de Vento
Collaborators: Ministry of Health, Brazil, Boehringer Ingelheim, Brainomix Limited, iSchemaView, Inc
Conditions Ischemic Stroke, Acute
Enrollment 466 participants
Start Date 2022-01-20
Primary Completion 2026-07 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2025-04-04